Company profile IDYA

Ideaya Biosciences Inc
ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene..., wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california. Show More
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences -synthetic lethality-focused precision medicine oncology company to provide analysis

Correlation between past revenue and IDEAYA Biosciences -synthetic lethality-focused precision medicine oncology company search interest

There is not enough data for IDEAYA Biosciences -synthetic lethality-focused precision medicine oncology company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences -synthetic lethality-focused precision medicine oncology company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences news to provide analysis

Correlation between past revenue and IDEAYA Biosciences news search interest

There is not enough data for IDEAYA Biosciences news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 15:09:30.

After 39 days of this quarter the interest is at 108.0. Based on that we can calculate that during remaining 52 days it will total up to 252.0.
IDEAYA Biosciences stock expected interest is significantly higher compared to previous quarter (+59.5%) and same quarter last year (+260.0%).

YearQ1Q2Q3Q4
20190
107
inf% QoQ
118
10.3% QoQ
132
11.9% QoQ
2020 196
inf% YoY 48.5% QoQ
132
23.4% YoY -32.7% QoQ
96
-18.6% YoY -27.3% QoQ
61
-53.8% YoY -36.5% QoQ
2021 63
-67.9% YoY 3.3% QoQ
109
-17.4% YoY 73.0% QoQ
54
-43.8% YoY -50.5% QoQ
0
-100.0% YoY -100.0% QoQ
2022 165
161.9% YoY inf% QoQ
60
-45.0% YoY -63.6% QoQ
54
0.0% YoY -10.0% QoQ
92
inf% YoY 70.4% QoQ
2023 70
-57.6% YoY -23.9% QoQ
185
208.3% YoY 164.3% QoQ
35
-35.2% YoY -81.1% QoQ
158
71.7% YoY 351.4% QoQ
2024 108
54.3% YoY -31.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and IDEAYA Biosciences stock search interestLast update: February 09 2024 15:09:29.
Correlation coefficient between keyword and revenue is -0.11
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 15:09:31.

The average 5 years interest of IDEAYA Biosciences stock was 7.64 per week.
The last year interest of IDEAYA Biosciences stock compared to the last 5 years has changed by 22.38%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 1.3%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences clinical trials to provide analysis

Correlation between past revenue and IDEAYA Biosciences clinical trials search interest

There is not enough data for IDEAYA Biosciences clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences pipeline to provide analysis

Correlation between past revenue and IDEAYA Biosciences pipeline search interest

There is not enough data for IDEAYA Biosciences pipeline to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences pipeline to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences investor relations to provide analysis

Correlation between past revenue and IDEAYA Biosciences investor relations search interest

There is not enough data for IDEAYA Biosciences investor relations to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences investor relations to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences target therapeutics to provide analysis

Correlation between past revenue and IDEAYA Biosciences target therapeutics search interest

There is not enough data for IDEAYA Biosciences target therapeutics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences target therapeutics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences molecular diagnostics to provide analysis

Correlation between past revenue and IDEAYA Biosciences molecular diagnostics search interest

There is not enough data for IDEAYA Biosciences molecular diagnostics to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences molecular diagnostics to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences precision medicine to provide analysis

Correlation between past revenue and IDEAYA Biosciences precision medicine search interest

There is not enough data for IDEAYA Biosciences precision medicine to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences precision medicine to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for IDEAYA Biosciences synthetic lethality to provide analysis

Correlation between past revenue and IDEAYA Biosciences synthetic lethality search interest

There is not enough data for IDEAYA Biosciences synthetic lethality to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for IDEAYA Biosciences synthetic lethality to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for IDYA
Earnings date: 2024-03-05 After close
Company name: Ideaya Biosciences Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T13:15:00Z

GlobeNewswire
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology

2026-05-07T12:32:04Z

Analyst Upgrades
Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $50

2026-05-05T06:00:00-04:00

PR Newswire
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-01T06:00:00-04:00

PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-04-30T06:00:00-04:00

PR Newswire
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

2026-04-21T10:15:00-04:00

PR Newswire
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma

2026-04-14T15:57:42Z

Analyst Upgrades
Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $35

2026-04-14T14:51:49Z

Analyst Upgrades
Wells Fargo Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $48

2026-04-14T14:18:23Z

Analyst Upgrades
RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $53

2026-04-14T13:46:56Z

Analyst Upgrades
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $58

2026-04-14T13:09:07Z

Analyst Upgrades
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $54

2026-04-13T06:00:00-04:00

PR Newswire
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma

2026-04-10T16:05:00-04:00

PR Newswire
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

2026-04-06T06:00:00-04:00

PR Newswire
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

2026-03-31T14:12:11Z

Analyst Upgrades
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $52 Price Target